Shatha H. Mohammad
Vol. 7, Jan-Jun 2019
Abstract:
Previously, diabetes mellitus was thought to be kidney disease. However, the role of the renal system in the development and maintenance of elevated glucose levels has piqued interest in the last decade. This has sparked the introduction of brand-name medications that block sodium-glucose transporter-2 (SGLT2) to improve glucose regulation while also encouraging calorie loss, and lower insulin, blood pressure, and uric acid levels. This study aimed to investigate the effects of dapagliflozin-5mg and dapagliflozin-10mg on serum creatinine, urinary protein/creatinine ratio, serum sodium (serum Na+), and serum potassium (serum K+). The study included 59 male and female patients with T2DM. After 6-months of treatment with dapagliflozin 5mg, dapagliflozin 10mg, there was significant modulation of the level of serum creatinine, serum K+ level, Urinary creatinine/protein ratio. The study concluded that dapagliflozin in a dose of 5mg, 10mg is associated with statistically significant elevation in serum creatinine and urinary protein/creatinine ratio after 6-months of treatment. No alteration in serum Na+ and serum K+ level with dapagliflozin 5mg but in a dose of 10mg, dapagliflozin causes significant hyperkalemia after 24-week treatment.